Search results
Earnings call: Amicus Therapeutics highlights solid Q1 growth, raises guidance
Investing.com· 7 days agoAmicus (NASDAQ: FOLD ) Therapeutics (NASDAQ: FOLD) has reported a strong start to 2024 with a 28%...
Maze lands new partner for Pompe drug, after Sanofi pact came apart
BioPharma Dive via Yahoo Finance· 6 days agoDive Brief: Biotechnology startup Maze Therapeutics has licensed a Pompe disease drug to Shionogi,...
After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M
FierceBiotech· 6 days agoIt appears Sanofi’s loss is Shionogi’s gain. Five months after the Federal Trade Commission (FTC) scuttled Sanofi’s attempt to acquire Maze Therapeutics’ Pompe disease ...
Shionogi secures licence for Maze’s Pompe disease treatment
Pharmaceutical Technology via Yahoo Finance· 6 days agoShionogi has concluded an exclusive global licence agreement for Maze Therapeutics’ MZE001, an oral...
Amicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Reven
Guru Focus· 6 days agoThe company, a global biotechnology leader dedicated to treating rare diseases, reported a significant 28% year-over-year increase in total revenue, reaching $110.4 million ...
Regulators caused breakup of potential $750 million drug deal — now they've blessed company's latest...
The Business Journals· 6 days agoLtd. Shionogi will pay the $150 million upfront for an exclusive worldwide license for MZE-001 — a...
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
Zacks· 7 days agoThe year-over-year improvement can be attributed to higher revenues from Galafold (migalastat) sales and incremental revenues from the sale of the newly approved combo drug, Pombiliti + Opfolda ...
Opinion | FTC Puts Pharmacy Benefit Managers, Private Equity in the Crosshairs
MedPage Today· 7 days agoIn Part 2 of this exclusive video interview, MedPage Today editor-in-chief Jeremy Faust, MD, and...